Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 6/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 3/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929435 | 0.87 | CCNT1 (0.52) | GRM2CDK9CTSACCNT1 | |
| SCHEMBL9929604 | 0.86 | PLG (0.48) | CSF1RGRM2HTR2AHTR2C | |
| SCHEMBL1440085 | 0.80 | LRRK2 (0.43) | CDK9CTSACCNT1LRRK2 | |
| SCHEMBL1439355 | 0.80 | CCNT1 (0.44) | CDK9CTSACCNT1ERN1LRRK2 | |
| SCHEMBL9929900 | 0.74 | HPGDS (0.50) | GRM2CDK9CDK1CDK2 | |
| SCHEMBL30292714 | 0.72 | GPBAR1 (0.49) | SLC9A1CDK9CCNT1 | |
| SCHEMBL31069507 | 0.72 | GPBAR1 (0.48) | CDK9CCNT1 | |
| SCHEMBL8940603 | 0.71 | ERN1 (0.51) | SLC9A1CDK9CCNT1ERN1LRRK2 | |
| SCHEMBL4973657 | 0.70 | CYP1A2 (0.54) | SLC9A1CTSA | |
| SCHEMBL29706670 | 0.70 | LMNA (0.52) | SLC9A1CDK9CCNT1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473502-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2012-07-11 | — | — | EP | claimed |
| EP-2473502-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | CSF1R 2747/4885SLC9A1 4076/4885GRM2 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.